Literature DB >> 18537756

Targeting vesicle trafficking: an important approach to cancer chemotherapy.

Paul K Wright1.   

Abstract

Cancer is a common disease in Western society that can affect any organ system. It has a high morbidity and mortality despite advances in treatment over the last hundred years. There is a clear need for new approaches to cancer chemotherapy including the possibility of reducing systemic adverse effects associated with current treatments. Vesicle trafficking is an essential cellular process that is perhaps not fully recognized. There is mounting evidence that vesicle trafficking, including the release of extracellular microvesicles, is a highly important process in tumorigenesis. Diverse aspects of tumourigenesis including invasion, metastasis, cell cycle regulation, angiogenesis, tumor immune privilege, neoplastic coagulopathy and multidrug resistance can be explained by altered vesicle trafficking in cancer cells. This paper reviews the evidence in the scientific and patent literature for the role of vesicle trafficking in tumourigenesis and suggests a number of targets and strategies that may be important for cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537756     DOI: 10.2174/157489208784638730

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  19 in total

Review 1.  Bugs, drugs and chemical genomics.

Authors:  Terry Roemer; Julian Davies; Guri Giaever; Corey Nislow
Journal:  Nat Chem Biol       Date:  2011-12-15       Impact factor: 15.040

2.  High CHMP4B expression is associated with accelerated cell proliferation and resistance to doxorubicin in hepatocellular carcinoma.

Authors:  Baoying Hu; Dawei Jiang; Yuyan Chen; Lixian Wei; Shusen Zhang; Fengbo Zhao; Runzhou Ni; Cuihua Lu; Chunhua Wan
Journal:  Tumour Biol       Date:  2015-02-11

3.  Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells.

Authors:  Ji Na Kong; Qian He; Guanghu Wang; Somsankar Dasgupta; Michael B Dinkins; Gu Zhu; Austin Kim; Stefka Spassieva; Erhard Bieberich
Journal:  Int J Cancer       Date:  2015-04-27       Impact factor: 7.396

4.  Rab34 regulates adhesion, migration, and invasion of breast cancer cells.

Authors:  Lixiang Sun; Xiaohui Xu; Yongjun Chen; Yuxia Zhou; Ran Tan; Hantian Qiu; Liting Jin; Wenyi Zhang; Rong Fan; Wanjin Hong; Tuanlao Wang
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

5.  Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma.

Authors:  Wei-Wei Dong; Quan Mou; Jian Chen; Jian-Tao Cui; Wen-Mei Li; Wen-Hua Xiao
Journal:  World J Gastroenterol       Date:  2012-04-21       Impact factor: 5.742

6.  RAB34 was a progression- and prognosis-associated biomarker in gliomas.

Authors:  Hong-jun Wang; Yang Gao; Ling Chen; Yong-li Li; Chuan-lu Jiang
Journal:  Tumour Biol       Date:  2014-12-13

7.  Overexpression of Rab27B is correlated with distant metastasis and poor prognosis in ovarian cancer.

Authors:  Ping Ren; Xiao-Qing Yang; Xiao-Lu Zhai; Yu-Quan Zhang; Jian-Fei Huang
Journal:  Oncol Lett       Date:  2016-06-29       Impact factor: 2.967

8.  CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells.

Authors:  Ching-Fong Liao; Shu-Hui Lin; Hung-Chang Chen; Cheng-Jeng Tai; Chun-Chao Chang; Li-Tzu Li; Chung-Min Yeh; Kun-Tu Yeh; Ying-Chun Chen; Tsu-Han Hsu; Shing-Chuan Shen; Woan-Ruoh Lee; Jeng-Fong Chiou; Shue-Fen Luo; Ming-Chung Jiang
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

Review 9.  The immune functions of phosphatidylserine in membranes of dying cells and microvesicles.

Authors:  Benjamin Frey; Udo S Gaipl
Journal:  Semin Immunopathol       Date:  2010-10-13       Impact factor: 11.759

10.  Estrogen regulates vesicle trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells.

Authors:  Paul K Wright; Felicity Eb May; Steve Darby; Rehan Saif; Tom Wj Lennard; Bruce R Westley
Journal:  Int J Clin Exp Pathol       Date:  2009-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.